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Background: A minority of breast cancer (BC) patients suffer from severe reaction 
to adjuvant radiotherapy (RT). Although deficient DNA double-strand break repair 
is considered the main basis for the reactions, pretreatment identification of high-risk 
patients has been challenging.
Methods: To retrospectively determine the etiology of severe local reaction to RT in 
a 39-year-old woman with BC, we performed next-generation sequencing followed 
by further clinical and functional studies.
Results: We found a −4 intronic variant (c.2251-4A>G) in trans with a synony-
mous (c.3576G>A) variant affecting the ATM DNA-repair gene (NG_009830.1, 
NM_000051.3) which is linked to autosomal recessive ataxia–telangiectasia (A–T). 
We verified abnormal transcripts resulting from both variants, next to a minor wild-
type transcript leading to a residual ATM kinase activity and genomic instability. 
Follow-up examination of the patient revealed no classic sign of A–T but previously 
unnoticed head dystonia and mild dysarthria, a family history of BC and late-onset 
ataxia segregating with the variants. Additionally, her serum level of alpha-fetopro-
tein (AFP) was elevated similar to A–T patients.
Conclusion: Considering the variable presentations of A–T and devastating impact 
of severe reactions to RT, we suggest a routine measurement of AFP in RT-candidate 
BC patients followed by next-generation sequencing with special attention to non-
canonical splice site and synonymous variants in ATM.
K E Y W O R D S
ataxia–telangiectasia, ATM, breast cancer, hypomorphic variants, normal tissue overreaction, 
radiotherapy, splice site variants
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1 |  INTRODUCTION
Breast cancer is the most frequent malignancy in women with 
an age-adjusted annual incidence of 94.2/100'000 in Europe 
(Senkus et al., 2015). A significant milestone in the treatment 
of early stage breast cancer has been a shift from mastec-
tomy toward breast-conserving surgery over the last decades 
(Association of Breast Surgery at BASO, 2009, 2009). To 
reduce local relapse, postoperative radiotherapy (RT) is cur-
rently standard (Bartelink et al., 2015; Darby et al., 2011).
The success of RT in eradicating cancer cells depends 
significantly on sufficient radiation dosage which is limited 
by overreactions in the tumor-surrounding normal tissues 
(OR). However, also patients treated with the same standard 
RT dosage may manifest with different degrees of mild to 
moderate OR, and a minority suffer from severe or even life 
threatening OR (Barnett et al., 2015; Granzotto et al., 2016).
Despite the efforts to anticipate the risk of OR by patient 
characteristics (such as age, hemoglobin level, comorbid con-
ditions, etc.), cellular radiosensitivity or apoptosis testing, or 
evaluating common genetic polymorphisms, to date the risk 
cannot be unequivocally predicted (Andreassen, 2005; Barnett 
et al., 2009, 2015; Bergom et al., 2019; Dong, Cui, Tang, 
Cong, & Han, 2015; Story & Durante, 2018; Terrazzino et al., 
2019). Nevertheless, deficient DNA double-strand break rec-
ognition or repair responsible for genome stability and cell 
survival, have been proposed as an important underlying etiol-
ogy of OR (Granzotto et al., 2016; West, 2003). Accordingly, 
rare biallelic germline variants in double-strand break repair 
genes have been linked to radiosensitivity in recessive ge-
netic disorders such as Fanconi anemia, Nijmegen breakage 
syndrome, and ataxia–telangiectasia (A–T) (Bentzen, 2006). 
Among them, A–T is remarkable for its broad clinical spec-
trum from "classical" with severe childhood-onset cerebellar 
ataxia, multisystem involvement, predisposition primarily to 
lymphoreticular cancer, and radiosensitivity, to " mild" or 
“variant” with relatively milder neurological impairments 
and fewer systemic symptoms (van Os, Hensiek, et al., 2019; 
Sutton et al., 2004; Verhagen et al., 2012). Especially patients 
with atypical or milder adult-onset presentations may remain 
undiagnosed for a long time (Claes et al., 2013; Dawson, 
Marles, Tomiuk, Riordan, & Gatti, 2015; van Os, Hensiek, 
et al., 2019). Defective DNA damage repair, impaired prote-
asome-mediated protein degradation (Wood et al., 2011), or 
nuclear accumulation of histone deacetylase 4 (HDAC4) (Li 
et al., 2012) in neurons have been proposed as possible mech-
anisms of neurodegeneration following ATM deficiency. It 
is likely that some residual ATM activity and possibly other 
protective mechanisms delay neurodegeneration in some A–T 
patients. After all, impaired DNA damage repair and genomic 
instability are the most likely explanations for cancer suscep-
tibility and radiosensitivity in ATM deficiency (Byrd et al., 
2012; Choi, Kipps, & Kurzrock, 2016; Fang et al., 2010). In 
general, patients with classical A–T harbor biallelic truncat-
ing ATM (OMIM *607585) variants resulting in the absence 
of ATM kinase activity, while patients with mild A–T harbor 
pathogenic biallelic variants of which at least one is missense 
or affecting the splice site preserving some protein expres-
sion and residual kinase activity (Byrd et al., 2012; Verhagen 
et al., 2009, 2012). While heterozygous carriers of deleterious 
ATM variants are at increased risk of breast cancer, there is no 
clear clinical evidence for their higher risk of OR or manifest-
ing A–T features (Bergom et al., 2019; Goldgar et al., 2011; 
Jerzak, Mancuso, & Eisen, 2018; Meyer et al., 2004; Modlin 
et al., 2019; Pinto et al., 2016).
Here, we detected two hypomorphic pathogenic variants 
in trans affecting ATM in a 39-year-old woman with uni-
lateral breast cancer and severe acute and late OR to adju-
vant RT (Figure 1A–C). This finding led to the diagnosis of 
mild A–T in the patient and her siblings (Figure 1D) after 
follow-up examination and functional studies. Our findings 
further broaden the spectrum of A–T patients who remained 
undiagnosed and manifested with severe OR after RT creat-
ing an immense physical, psychological and financial burden. 
We therefore suggest considering the possible diagnosis of 
mild or variant A–T prior to the application of RT in breast 
cancer patients especially in those with younger age, neuro-
logical features, and/or a positive family history.
2 |  MATERIALS AND METHODS
2.1 | Genetic and transcriptional studies
Genetic testing was performed on a diagnostic basis with 
subsequent informed consents for publication.
Genomic DNA was extracted from EDTA blood of the 
index patient (II-8) and other available siblings (II-5, II-9, II-
11) (Figure 1D). Next-generation sequencing (NGS) of 4813 
known disease genes was performed for the index patient 
using the TruSight™ One Sequencing Panel (Illumina, CA, 
USA) with paired-end sequencing (MiSeq Reagent Kit v3, 200 
Fwd-200 Rev) on a MiSeq System (Illumina, CA, USA). The 
data were analyzed using NextGENe Software (SoftGenetics, 
PA, USA) for exonic and splice site variants considering both 
dominant and recessive modes of inheritance. The average 
depth of coverage was 198x, and ~95.7% of the targeted bases 
were assessed by ≥20 independent sequence reads.
Confirmation and segregation analysis of candidate ATM 
(NG_009830.1, NM_000051.3) variants were done after PCR 
amplification by Sanger sequencing using an ABI Genetic 
Analyzer 3730 (Applied Biosystems, Foster City, California).
For transcriptional analysis, total RNA was extracted 
from blood and fibroblast samples of the index patient 
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(II-8) and healthy controls using the PAXgene™ Blood 
RNA Kit 50 or RNeasy Plus Mini Kit 50 (Qiagen, Hilden, 
Germany), respectively. Reverse transcription was per-
formed using the Transcriptor High Fidelity cDNA 
Synthesis Kit (Roche, Mannheim, Germany). To evaluate 
the splicing effect of the variants, targeted Sanger sequenc-
ing was performed after PCR amplification of the cDNA 
using primers spanning exons 14–16, and 23–25 of ATM 
(NG_009830.1, NM_000051.3). Additionally, we per-
formed allele-specific RT-PCR targeting either the wild-
type or mutated sequence of exon 14/15 and wild-type 
sequences in exon 25. ATM mRNA expression levels were 
assessed in fibroblast cDNA of the patient, two healthy 
controls, and a primary melanoma culture (Cellosaurus 
M010817, as positive control) using customized SYBR 
green qPCR for exons 3 and 4 of the gene on a Roche 
LightCycler480. ATM mRNA expression levels were nor-
malized to Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) levels. For statistical analyses, the means of 
three biological replicates were compared using one-way 
ANOVA and Tukey's test for multiple comparisons.
Chromosomal analysis was performed using patient's pe-
ripheral lymphocytes stimulated with phytohemagglutinin 
for 72 hours followed by GTG banding at a 450–500 banding 
resolution.
2.2 | Immunoblotting for ATM protein 
level and kinase activity
For protein evaluations, primary fibroblasts of the index pa-
tient (II-8), two healthy controls and a primary melanoma 
F I G U R E  1  Local post-radiotherapy reactions in the index patient (a–c), and her family pedigree (d). (a) Moist desquamation and skin 
abrasions (RTOG acute reaction grade 3) developing within few days after the last session of radiotherapy (RT, 66 Gy), (b) severe fibrosis and 
shrinkage together with telangiectasia after 1 year, and (c) marked telangiectasia, severe fibrosis, and necrosis (RTOG late reaction grade 3–4), 
requiring a surgical intervention 3 years after RT. (d) Pedigree of the family showing the segregation of ATM variants and clinical features. Index 
patient is indicated by the black arrow
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culture (M010817, as positive control) were lysed in TNN 
buffer (50 mM Tris pH 7.5, 250 mM NaCl, 5 mM EDTA, 0.5% 
NP-40, 50 mM NaF, 0.5 mM EGTA, 1x cOmplete™ and 1x 
PhosStop™ (both Roche). The protein concentration was de-
termined using a bicinchoninic acid assay (Pierce BCA kit, 
Thermo SCIENTIFIC, Rockford, IL, USA). Samples were 
then boiled in 1x Laemmli Sample Buffer and run for SDS–
PAGE using 4%–20% Mini-PROTEAN TGX Stain-Free Gels 
(Bio-Rad). Gels were blotted using PVDF Trans-Blot Turbo 
Transfer Packs, according to the manufacturer's protocols using 
a trans-blot turbo blotting device (Bio-Rad). The following 
antibodies were used: total ATM (D2E2) rabbit monoclonal 
antibody, recognizing the C-terminal portion of human ATM 
(Cell Signaling Technology, cat. no. 2873), P-ATM S1981 
(EP1890Y) rabbit monoclonal antibody (Abcam, cat. no. 
ab81292), p44/42 MAPK (ERK1/2) (L34F12) mouse mono-
clonal antibody (Cell Signaling Technology, cat. no. 4696), and 
β-actin (AC-74) mouse monoclonal antibody (Sigma, cat. no. 
A5316). Signals were detected using Clarity™ ECL Western 
Blotting Substrate (Bio-Rad) on a Fusion FX imager (Vilber 
Lourmat, Marne-la-Vallée, France).
To evaluate the ATM function, we performed a 24-hr 
treatment course of oxaliplatin (SelleckChem, cat. no. 
S1224) which was obtained lyophilized, dissolved in DMSO 
to a stock solution of 10 mM, and then, used 1:1,000 in cell 
culture experiments. DMSO (1:1,000) was used as the ve-
hicle control. Oxaliplatin is a platinum compound which 
provokes DSBs (Faivre, Chan, Salinas, Woynarowska, & 
Woynarowski, 2003), and therefore, activates ATM by in-
creased autophosphorylation of ATM at S1981 (So, Davis, 
& Chen, 2009).
2.3 | Cell cultures
Standard skin-punch biopsies from the index patient (II-8) 
with pathogenic ATM variants and healthy controls were ob-
tained and cultured according to standard protocols.
Primary melanoma culture M010817 was obtained from 
R. Dummer and M. Levesque (Shakhova et al., 2012) and 
cultured in RPMI-1640+GlutaMax, supplemented with 10% 
of FCS (both Gibco, Zug, Switzerland).
2.4 | Radiosensitivity testing
Subcultures of patient fibroblasts were seeded at a density of 
4000/cm2 in DMEM with stable glutamine and 15% of FCS 
(both Sigma, St. Louis, MO, USA) and DNA damage was 
elicited by exposure of cells to 6 MV X-ray photons provided 
by a linear accelerator (Primus series, Siemens Healthcare, 
Erlangen, Germany) at a dose rate of 3 Gy/min at assay time 
0. Matched cultures from treated and untreated fibroblasts 
were harvested 48  hr postirradiation using Accutase (PAN 
Biotech, Aidenbach, Germany). For cell cycle analysis, de-
tached cells were pelleted and resuspended at a density of 
106/ml in staining buffer containing 4 µg/ml of 4′,6-diamid-
ino-2-phenylindole (DAPI), 100 mM of Tris pH 7.4, 154 mM 
of NaCl, 1 mM of CaCl2, 0.5 mM of MgCl2, 0.2% of BSA, 
0.1% of NP40 in dH2O (Sigma) for a minimum of 30 min-
utes at 4°C in the dark (Darzynkiewicz, Huang, & Zhao, 
2017). Bivariate flow histograms were recorded on an ana-
lytical, triple laser-equipped flow cytometer (LSRII, Becton 
Dickinson, Franklin Lakes, NJ, USA) using UV excitation/
emission at 355/460 nm and FACSDiva software for data ac-
quisition. The resulting cell cycle distributions reflecting cel-
lular DNA content and cell cycle progression were quantified 
by means of the MPLUS AV software package to assess G2 
phase accumulation (Phoenix Flow Systems, San Diego, CA, 
USA) (Schindler & Hoehn, 1999).
3 |  RESULTS
3.1 | Patient's clinical course and family 
history
The index patient (II-8, Figure 1D) was a 39-year old fe-
male of Turkish origin diagnosed with multifocal invasive 
ductal carcinoma of the left breast (stage pT2 pN1(1/17) 
M0, G3, ER, and PR positive, HER2 negative). Her treat-
ment consisted of a lumpectomy followed by four cycles 
of adjuvant chemotherapy with Epirubicin (130  mg) and 
Endoxan (900 mg) starting 1 month after the surgery, and 
adjuvant RT of the left breast starting 2 months after the 
last chemotherapy cycle. The RT protocol comprised per-
cutaneous irradiation of the left breast with 25 fractions of 
2 Gy (cumulative dose 50 Gy) and an additional boost dose 
of 16 Gy (8 × 2 Gy) to reach a final dose of 66 Gy during 
45 days.
During RT, she developed acute skin reactions of grade 1–2 
(according to the Radiation Therapy Oncology Group (RTOG) 
toxicity grading) including mild edema and erythema of the 
left breast, slight erythema in the left axilla, skin irritation, and 
hyperpigmentation under the left mammilla and axilla, as well 
as light pruritus and pain which were managed conservatively. 
These reactions were adequate for the dose, however, within few 
days after the last session (66 Gy), she began to develop moist 
desquamation and skin abrasions as well as strong stabbing pain 
and tenderness of the left breast (RTOG acute reaction grade 
3, Figure 1A) which were managed with wound cleaning and 
topical analgesics. While the abrasions became smaller over 
time with no evidence of infection, skin fibrosis and granulation 
occurred which eventually led to severe fibrosis and shrinkage 
together with telangiectasia after a year (Figure 1B). Ultimately, 
she developed marked telangiectasia over the left breast, severe 
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fibrosis, and necrosis (RTOG late reaction grade 3–4, Figure 
1C) requiring a surgical intervention 3 years after RT.
Neurological examination of the index patient at this stage 
(age 43 years) revealed psychomotor restlessness, some parak-
inesia, and a dystonic posture of the head with intermittent 
irregular tremor and mild dysarthria, considered suggestive 
of a choreatiform movement disorder, but no ataxia or oculo-
motor abnormalities. She had neither oculocutaneous telan-
giectasia nor a history of pulmonary problems or recurrent 
infections. Her brain MRI as well as serum immunoglobulin 
levels (IgG 14 g/L (8.0–15.0 g/L), IgM 1.3 g/L (0.6–2.8 g/L), 
and IgA 3.0 g/L (0.8–3.4 g/L) were reported normal. Serum 
α-fetoprotein (AFP) determined once at the age of 43 years 
was elevated (55 U/mL, reference value <10 U/mL).
She had two sisters (II-3 and II-11, Figure 1D) who were 
also diagnosed with breast cancer at the age of ~40 years. One 
of them (II-3) deceased due to an advanced breast cancer with-
out having received RT, and the other (II-11) had bilateral breast 
cancer but did not undergo RT because of the severe OR in her 
sister. A brother of them (II-5) was later reported by the patient 
to suffer from late-onset progressive ataxia having started in his 
30s, but no cancer at the age of 60 years, and another brother 
(II-7) had a history of epilepsy since 20 years of age.
3.2 | Genetic and transcriptional findings
Targeted exome sequencing in the index patient revealed 
two heterozygous variants in the ATM gene, an uncharac-
terized intronic variant located at −4 of exon 15 (c.2251-
4A>G) and a previously characterized synonymous variant 
of the last nucleotide of exon 24 (c.3576G>A). Our mRNA 
analysis revealed the inclusion of three nucleotides (TAG) 
in the ATM transcript by the −4 splice site variant causing 
an insertion of a premature stop codon (r.2250_2251instag, 
p.(Ser751*)) (Figure 2A and 2C), and an in-frame skipping 
of exon 24 by the exonic synonymous variant resulting in 
a predicted deletion of 58 amino acids (r.3403_3576del, 
p.(Ser1135_Lys1192del)) (Figure 2A and 2C). By allele-spe-
cific RT-PCR, we observed a faint band indicating a wild-
type transcript resulting from one or two leaky alleles in the 
patient (Figure 2B and 2C). Notably, we did not observe a 
statistically significant reduction of the ATM mRNA levels in 
cultured skin fibroblasts of the index patient compared to two 
healthy controls (Figure 3A) possibly due to a transcriptional 
dosage compensation process. Compared to the fibroblasts, 
ATM mRNA levels were significantly higher in the primary 
melanoma cell cultures which were used as positive control 
(p < 0.01) (Figure 3A).
Moreover, chromosome analyses of the patient's periph-
eral lymphocytes revealed rearrangements of chromosomes 
5, 7, 12, and 14 in 6.5% of the 77 evaluated metaphases 
(Figure 3C) suggestive of chromosomal instability.
Among siblings of the index patient whose DNAs were 
available, we observed the presence of both sequence variants 
in the sister (II-11) with a history of bilateral breast cancer, and 
in the brother (II-5) with late-onset progressive ataxia. One un-
affected sister (II-9) at the age of 45 was heterozygous for the 
−4 splice site variant. DNA samples from the deceased sister 
(II-3) with a history of advanced breast cancer and the brother 
(II-7) with epilepsy were not available for testing (Figure 1D). 
Accordingly the ATM variants were compound heterozy-





3.3 | ATM protein level and kinase activity
Total ATM protein levels, though still detectable, were sig-
nificantly lower in the index patient's fibroblasts compared 
to the control fibroblast samples (Figure 3B, total ATM) in-
dicating reduced amounts of detectable ATM protein despite 
the unchanged mRNA expression. This is possibly due to a 
misfolding or instability of the aberrant protein.
In addition, while the levels of phosphorylated ATM at 
serine 1981 were increased upon oxaliplatin treatment in con-
trol fibroblasts and the primary melanoma cell culture, we 
detected only a very faint induction in the patient's fibroblasts 
suggestive of a significantly reduced ATM kinase activity in 
her fibroblasts (Figure 3B, P-ATM S1981).
3.4 | Cellular radiosensitivity
Patient's fibroblasts demonstrated definitive elevation of 
the G2 phase compartment (Figure 3D) as manifestation of 
delay and arrest in cell cycle progression which is consistent 
with unresolved replication stress likely due to the genomic 
instability. Further disproportional increase of G2 phase ac-
cumulation after ionizing irradiation of fibroblasts (Figure 
3D) confirmed the underlying genetic instability and cellu-
lar radiosensitivity (Branzei & Foiani, 2010; Seyschab, Sun, 
Friedl, Schindler, & Hoehn, 1993).
4 |  DISCUSSION
Our findings illustrate the importance of considering breast 
cancer before the age of 45–50 years as the first apparent sign 
of mild or variant, late-onset A–T. Milder or unspecific neu-
rological phenotypes such as extrapyramidal symptoms, sig-
nificantly lesser presentations of telangiectasia or other A–T 
features, and less and later-onset malignancies with a shift 
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from lymphoreticular to solid cancers have been previously 
linked to the residual ATM kinase activity in patients with 
hypomorphic combinations of ATM variants (Gilad et al., 
1998; Verhagen et al., 2009, 2012). Van Os, Hensiek, et al. 
(2019) defined six groups of neurological trajectories for 
mild forms of A–T with the mildest group showing a mean 
age at diagnosis of 35.8  years with extrapyramidal signs 
manifesting not later than the age of ~30 years, and ataxia 
and polyneuropathy not later than the age of ~40 years. Now 
our and the few published reports indicate that neurological 
signs may become apparent even later resulting in severe OR 
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(Table 1) (Byrd et al., 2012; Fang et al., 2010; Stankovic 
et al., 1998). Retrospectively, family history of our patient 
with ataxia in an older brother and breast cancer in an older 
sister might have been suggestive of mild A–T, however, 
initially the brother's disease was not reported. Nevertheless, 
nowadays most pedigrees are rather small, and thus, family 
history becomes less informative which may delay or thwart 
the clinical suspicion of mild A–T. Serum AFP levels have 
repeatedly been reported to be elevated in patients with both 
classical and mild A–T (Gilad et al., 1998; van Os, Hensiek, 
et al., 2019; Verhagen et al., 2009, 2012) with biallelic patho-
genic variants in ATM as held true for the index patient pre-
sented here. Therefore, serum AFP screening in women with 
breast cancer before the age of 45–50 years might be con-
sidered before starting adjuvant RT. However, since serum 
AFP levels above 10 U/ml have been also found in liver 
cancer, cirrhosis and gastric cancer, and to a lower extent in 
breast cancer (He, Lu, & Zhang, 2019), the definite diagnosis 
should be established by germline genetic testing. There are 
also a few examples of normal AFP levels in A–T patients 
and the possibility of false negative AFP or laboratory errors 
has been considered (Verhagen et al., 2012). Therefore, any 
neurological feature and/or positive family history should 
prompt genetic testing in patients with normal levels of AFP. 
Moreover, in patients with familial breast cancer, genetic test-
ing should not be restricted to BRCA1 and 2 (OMIM *113705 
and *600185) testing, but include at least ATM, too. This is 
especially important for genetic counseling of the extended 
family who may harbor heterozygous or biallelic ATM vari-
ants with different risk scores for developing breast cancer 
and OR after adjuvant RT. In addition, ATM testing might be 
of importance for considering the emerging targeted thera-
pies in ATM-deficient cancers (Choi et al., 2016).
The final diagnosis of heterozygous carriers or affected 
individuals with (mild or variant) A–T should be attempted 
to be achieved by germline testing of ATM. However, ATM is 
a large gene and pathogenic variants may remain undetected 
by standard diagnostic approaches. The two germline ATM 
variants detected in trans in our patient were a previously re-
ported synonymous splice site and a −4 intronic variant of 
unknown significance. The synonymous variant c.3576G>A 
was shown before (Gilad et al., 1998) and confirmed by us 
to cause exon 24 skipping and predicted in-frame deletion 
of 58 amino acids. This variant has been previously reported 
in homozygous or compound heterozygous states in patients 
presenting with milder classic A–T presentations (Gilad 
et al., 1998; Jacquemin et al., 2012; van Os, Chessa, et al., 
2019). The c.2251-4A>G variant was shown by us to cause 
a premature stop codon with the transcript likely undergoing 
nonsense-mediated decay with some leakiness. This variant 
has not been reported causative before, but was mentioned as 
a variant of uncertain significance in a large study of individ-
uals who were referred for genetic testing with a hereditary 
cancer panel and the majority had family history of breast 
and/or ovarian cancer (Tsaousis et al., 2019). Co-segregation 
with the phenotype in our family, aberrant splice site effects 
at mRNA level, profound reduction of ATM protein and its 
kinase activity, and considerable radiosensitivity detected in 
the fibroblasts of our index patient support the causality of 
these apparently hypomorphic variants.
The majority of earlier attempts of systematic searches 
for ATM germline variants in breast cancer patients with 
OR either did not reveal any ATM mutation likely because 
of using less-sensitive methods compared to NGS, or de-
tected variants with questionable pathogenicity consider-
ing current knowledge (Andreassen et al., 2006; Appleby 
et al., 1997; Bremer et al., 2003; Iannuzzi, Atencio, Green, 
Stock, & Rosenstein, 2002; Ramsay, Birrell, & Lavin, 1998). 
Nevertheless, Fang et al. (Fang et al., 2010) detected ATM 
protein levels of 8–45% in lymphoblastoid cell lines of 4/12 
F I G U R E  2  Splice site effects of the ATM (NG_009830.1, NM_000051.3, NP_000042.3) variants in fibroblast cells of the index patient: 
c.2251-4A>G resulting in the insertion of a premature stop codon (r.2250_2251instag, p.(Ser751*)) and likely nonsense-mediated mRNA decay, 
and c.3576G>A leading to an in-frame deletion of exon 24 (r.3403_3576del, p.(Ser1135_Lys1192del)). (a) Upper agarose gel showing similar RT-
PCR bands sizing about 220 bp from primers spanning exons 14–16 of ATM encompassing the c.2251-4A>G variant (-4 of exon 15) in the index 
patient (Pt.) and controls (Ctl.1 and 2). Left electropherograms from Sanger sequencing of the patient's RT-PCR product showing both the wild-
type sequence and a low level mutated sequence with the inclusion of a “TAG” codon (r.2250_2251instag, p.(Ser751*)) indicating the remnants of 
the aberrant allele undergoing nonsense-mediated mRNA decay. Lower agarose gel showing RT-PCR bands from primers spanning exons 23–25 
of ATM encompassing the variant c.3576G>A (in exon 24) in the index patient and controls. Next to a faint band with the wild-type fragment size 
(377 bp), a smaller aberrant band (203 bp) is visible in the patient lane. Right electropherograms from Sanger sequencing of the patient's RT-PCR 
products showing the aberrant fragment to lack exon 24 corresponding to the loss of 174 bps (r.3403_3576del, p.(Ser1135_Lys1192del)). Low level 
wild-type sequence (exon 24) consistent with the faint band of the expected size may indicate remnants of the decayed or leaky wild-type alleles. 
(b) Agarose gel showing allele-specific RT-PCR bands from primers spanning exons 14–25 of ATM in the index patient and controls. Forward-1 
targets the wild-type, forward-2 contains the "TAG" inclusion at the 3′ end, and reverse targets the wild-type. RT-PCR with forward-1 and reverse 
(left) shows a shorter product (1,262 bp) corresponding to the mutated allele with lack of exon 24, and a very faint band of the expected size 
(1,436 bp, better visible in the long exposure) likely indicating the expression of leaky wild-type transcript in the patient. RT-PCR with forward-2 
and reverse (right) shows a faint product of the expected size (1,436 bp) corresponding to the mutated allele with the inclusion of "TAG" seen in the 
patient, only. (c) Schematic structure of ATM protein with the affected sites highlighted. NLS: nuclear localization signal. LZ: leucine zipper. FAT: 
FRAP/ATM/TRRAP domain. PI3 K: PI3K-related kinase domain. FATC: FAT C-terminal
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(33%) breast cancer patients with severe acute and/or late OR 
to adjuvant RT which could be explained by pathogenic bi-
allelic ATM variants in only one of the four patients with the 
lowest ATM protein level (8%). This patient presented with 
breast cancer at the age of 50 years and severe late OR but no 
further details have been provided (Table 1).
Accordingly, the lack of NGS-based studies with compre-
hensive assessment of all ATM variants may have led to an un-
derestimation of biallelic pathogenic variants in ATM, which 
currently represents the strongest monogenic etiology of severe 
OR in breast cancer patients. In line with the finding in our 
index patient, ER and PR positive invasive ductal carcinomas 
F I G U R E  3  ATM mRNA and protein expression and kinase activity (a and b), chromosomal rearrangements (c), and radiosensitivity test in 
fibroblast cells of the index patient (d) indicating residual ATM activity and the consequent genomic instability, respectively. (a) ATM mRNA 
expression levels in the fibroblast cells of the index patient are compared to two healthy controls, and a primary melanoma culture (positive 
control). Values are expressed as ΔCt normalized to GAPDH with positive control set arbitrarily as 0 (a higher ΔCt value indicates lower mRNA 
abundance). While ATM mRNA levels were significantly higher in the positive control (p < 0.01), no statistically significant difference between 
the index patient and healthy controls was seen (three biological replicates). (b) Immunoblots of whole cell protein extracts from the same cultures 
as in (a) show significantly lower level of total ATM protein, and a very faint induction of phosphorylated ATM (at serine 1981) following 
oxaliplatin (oxali) treatment in the patient's fibroblasts compared to the controls. Cells were treated with 10 µM oxali (+) or vehicle control (−) 
for 24 hr. ERK1/2 and β-actin were used as loading controls. The experiment was repeated two times and one representative blot is shown (s.e.: 
short exposure, l.e.: long exposure). (c) Examples of chromosomal breakage in three different metaphases including breakage on chromosome 7 
(7q22-qter terminal on chromosome 12p) in the upper panel, and breakage on chromosomes 14q and 5q in the lower panel are shown, which were 
detected in the patient's peripheral lymphocytes. (d) Radiosensitivity testing of patient's fibroblast cells toward ionizing radiation showing mildly 
increased G2 compartment in the absence of irradiation (upper left panel, G0/G1 56.4%, S 20.8%, G2 22.8% (arrow); normal G2 <16%) compared 
to an age-matched control (upper right panel, G0/G1 77.4%, S 12.6%, G2 10.0%), and moderately elevated G2 phase accumulation after irradiation 
at a dosage of 1.5 Gy (lower left panel, G0/G1 53.4%, S 19.0%, G2 27.6% (arrow), normal <24%) compared to an age-matched control (lower right 


























T A B L E  1  Summary of patients diagnosed with mild ataxia–telangiectasia after ORa to adjuvant radiotherapy for breast cancer
Study Stankovic et al. (1998) Fang et al. (2010)
Mandigers et al. 
(2011) Byrd et al. (2012) This study
Gender Female Female Female Female Female
Age at A–T 
diagnosis (years)
44 50 42 44 43
Type of breast 
cancer
Right side invasive ductal carcinoma 
at 44 years, contra-lateral intraductal 
carcinoma in situ at 48 years
Not reported Ductal carcinoma 
(T2N2M0, ER+, 
Her2+) at 42 years
Right side carcinoma 
(T2N2, G2, ER+) at 
44 years
Left side invasive ductal carcinoma 
(T2N1M0, G3, ER+, PR+, HER2-) at 
39 years













skipping of exon 11 and 












Protein level Normal Reduced Not reported Reduced Reduced
Kinase activity Not reported Residual Not reported Residual Residual
Neurological 
features
Truncal ataxia and progressive dysarthria 
since early 20s, peripheral ataxia and 
oculomotor apraxia at 48 years
Not reported Unexplained, 
childhood-onset
choreoathetosis
Only a mild axonal 
polyneuropathy
Psychomotor restlessness with some 
parakinesia, dystonic posture of the head 
with intermittent irregular tremor, mild 
dysarthria




3 years later (treated), 
she died a year after 
without evidence of 
cancer recurrence
None None
Serum level of 
alpha-fetoprotein
Normalb Not reported Elevated (146.4 U/ml) Not reported Elevated (55 U/ml)
Family history Mild childhood-onset A–T in a brother, 
similar neurological course and invasive 
ductal carcinoma of the right breast at the 
age of 50 years in a sister, all harboring 
the same homozygous variant
Had relatives diagnosed 
with breast cancer
Not reported Not reported Severe late onset ataxia in a brother, breast 
cancer at the age of ~40 years in two sisters, 
the brother and a sister were tested and 
harbored the same bi-allelic variants
aOR: overreactions in the surrounding normal tissues after radiotherapy. 
bThe value and the age of sampling was not reported. 
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have been more frequently observed in ATM-associated breast 
tumors (Decker et al., 2017; Renault et al., 2018).
Taken together, our findings highlight the difficulty of rec-
ognizing mild or variant forms of A–T which may remain undi-
agnosed till presenting with breast cancer and severe OR to RT, 
thus, creating a massive burden for the patient and health care 
system. Therefore, we suggest a primary screening for elevated 
levels of serum AFP in RT-candidate breast cancer patients fol-
lowed by NGS-based testing of cancer genes including ATM 
(Figure 4). To distinguish between heterozygous carriers and 
patients with biallelic variants, it is essential to consider all the 
ATM variants including the non-canonical intronic and synony-
mous exonic variants for their mRNA splicing effects.
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